Congratulations Ann Partridge MD, MPH !

Please join the program on 5/31/2024 at ASCO - for all (international) medical graduate community - all welcome! Great discussion and stories! ASCO Nazli Dizman Toni Choueiri, MD Jame Abraham, MD, FACP Ziad Bakouny, MD, MSc Olufunmilayo Olopade Neeraj Agarwal, MD, FASCO Tanios Bekaii-Saab, MD Komal Jhaveri Narjust Florez, MD, FASCO Sumanta K. Pal, MD, FASCO

Erica Salehi, our amazing Research Dietician Memorial Sloan Kettering Cancer Center and soon to be Yale University PhD candidate, presents precision nutrition interventions in the context of exercise oncology. Grateful to our team for representing us at American College of Sports Medicine while I’m at another exciting ASCO meeting!

Ongoing panel discussion with leaders in understanding mentorship and overcoming structural barriers. First big takeway: You never know if you will get an opportunity unless you ask! #IMGOncCoP

What a fantastic initiative and thanks to ASCO for supporting this! Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Narjust Florez, MD, FASCO Neeraj Agarwal, MD, FASCO IMG Oncologists Tanios Bekaii-Saab, MD Ziad Bakouny, MD, MSc Nazli Dizman OncoAlert

A great afternoon for Developmental Therapeutics discussion and presentations at #ASCO24. Now up in Hall D1 is the highly anticipated oral abstract session on Dev Therapeutics-Targeted Agents track, co-chaired by fantastic ASCO committee members Manish Sharma, MD and Komal Jhaveri !

With the amazing ⁦Sherry Shen⁩ , rising star ⁦Memorial Sloan Kettering Cancer Center⁩ at our poster ⁦⁦ASCO⁩ looking at sequential use of agents targeting the PI3K/AKT/mTOR pathway for PIK3 mutant ER pos MBC

Komal Jhaveri Memorial Sloan Kettering Cancer Center ASCO Grateful for your mentorship Komal Jhaveri and thank you GRASP for selecting our poster for an advocate choice award!

“Attitude is a little thing that makes a big difference.” Let’s continue to bring the right attitude to work and in life as positive attitude is truly contagious! Happy Nationals Doctors day! Memorial Sloan Kettering Cancer Center MSK Department of Medicine

Hear the latest evidence supporting the use of new therapies for patients with HER2+ & #HER2 low, HR+ #BreastCancer from Drs. Komal Jhaveri, Javier Cortes MD PhD, G Curigliano MD PhD & Ian Krop: bit.ly/42zvAtn #ASCO24 #MedEd Living Beyond Breast Cancer GRASP

Hear the latest evidence supporting the use of new therapies for patients with HER2+ & #HER2 low, HR+ #BreastCancer from Drs. Komal Jhaveri, Javier Cortes MD PhD, G Curigliano MD PhD & Ian Krop: bit.ly/42zvAtn #ASCO24 #MedEd Living Beyond Breast Cancer PeerView

Get recommendations from the experts for identifying patients with HER2+ and #HER2 low, HR+ #BreastCancer & selecting/sequencing current & emerging treatments! Komal Jhaveri Javier Cortes MD PhD G Curigliano MD PhD #ASCO24 #MedEd bit.ly/42zvAtn With Living Beyond Breast Cancer PeerView

Important data to optimize axillary management and outcomes for patients MSK Department of Medicine Memorial Sloan Kettering Cancer Center #bcsm

Interesting real world analysis of outcomes with chemotherapy in HR+/HER2- MBC. Most used first line chemo: capecitabine. rwPFS for 1L chemo ~7 months, progressively shorter for subsequent lines. Consistent with recent trials in this space. #bcsm esmoopen.com/article/S2059-…

linkedin.com/posts/komal-jh…

Back to back JCO combo by Komal Jhaveri et al., with the results of the EMBER phase 1/2b trial of imlunestrant combos + the phase 1/2b trial of inavo/palbo/ET which laid the foundations for INAVO120. Congrats Komal and coauthors! ascopubs.org/doi/10.1200/JC… ascopubs.org/doi/10.1200/JC…

1) Imlunestrant at RP2D of 400mg- mPFS 7.2 mo 2) Imlunestrant + Abemaciclib in CDK naive patients mPFS19.2 mo 3)Imlunestrant + Everolimus 16 mo, Imlunestrant + Alpelisib 9 mo- no DDI or new safety signals.Activity in combination regardless of ESR1m. Await EMBER 3 results now